Hematologic and clinical features at presentation in patients with PMF according to their JAK2 V617F allele burden
| Feature . | JAK2V617F allele burden (%) . | P . | |||
|---|---|---|---|---|---|
| 1-25 . | 26-50 . | 51-75 . | 76-100 . | ||
| No. | 17 | 43 | 31 | 36 | |
| Median age, y (range) | 58 (38-90) | 63 (28-90) | 65 (28-77) | 60.31 (21-86) | .72 |
| Median follow-up, mo (range) | 16 (1-46) | 24 (1-84) | 26 (3-101) | 45 (1-237) | <.001* |
| Females, no. (%) | 4 (23.5) | 21 (48.8) | 12 (38.7) | 14 (38.9) | .40 |
| Median JAK2 V617F allele burden (range) | 15.5 (5-25) | 41 (27-50) | 66 (52-75) | 90.5 (77-100) | — |
| Median white blood cell count, ×109/L (range) | 10.26 (3.01-26.85) | 9.47 (3.73-106.15) | 9.40 (3.70-40.0) | 13.40 (3.40-40.60) | .03* |
| Median hemoglobin, g/L (range) | 128 (54-173) | 122 (61-175) | 134 (70-171) | 136 (56-180) | .05* |
| Median platelets, ×109/L (range) | 380.5 (45-1392) | 386 (49-1089) | 410 (42-1088) | 379 (75-2011) | .95 |
| Median LDH, U/L (range) | 712 (193-2981) | 745 (162-2497) | 600 (120-1958) | 700 (225-2166) | .83 |
| Blast ≥1, no. (%) | 10 (58.8) | 9 (33.3) | 7 (35) | 12 (50) | .21 |
| Median CD34+ cell, % (range) | 0.23 (0-3.1) | 0.19 (0.01-34) | 0.09 (0.02-3.43) | 0.25 (0.02-1.32) | .98 |
| Median CD34+ cell, ×109/L (range) | 22.8 (1.4-244) | 17.54 (0.26-800) | 7.06 (2.72-476) | 43.0 (3.0-130.0) | .93 |
| Splenomegaly >15 cm from LCM, no. (%) | 1 (5.8) | 7 (16.2) | 8 (25.8) | 9 (25.0) | .003* |
| Constitutional symptoms, % | 4 (23.5) | 11 (25.6) | 6 (19.3) | 17 (47.2) | .04* |
| Leukemia transformation, no. (%) | 0 | 4 (9.3) | 2 (6.4) | 3 (8.3) | .09 |
| Deaths, no. (%) | 6 (35.3) | 7 (16.3) | 1 (3.2) | 1 (2.8) | .007* |
| Feature . | JAK2V617F allele burden (%) . | P . | |||
|---|---|---|---|---|---|
| 1-25 . | 26-50 . | 51-75 . | 76-100 . | ||
| No. | 17 | 43 | 31 | 36 | |
| Median age, y (range) | 58 (38-90) | 63 (28-90) | 65 (28-77) | 60.31 (21-86) | .72 |
| Median follow-up, mo (range) | 16 (1-46) | 24 (1-84) | 26 (3-101) | 45 (1-237) | <.001* |
| Females, no. (%) | 4 (23.5) | 21 (48.8) | 12 (38.7) | 14 (38.9) | .40 |
| Median JAK2 V617F allele burden (range) | 15.5 (5-25) | 41 (27-50) | 66 (52-75) | 90.5 (77-100) | — |
| Median white blood cell count, ×109/L (range) | 10.26 (3.01-26.85) | 9.47 (3.73-106.15) | 9.40 (3.70-40.0) | 13.40 (3.40-40.60) | .03* |
| Median hemoglobin, g/L (range) | 128 (54-173) | 122 (61-175) | 134 (70-171) | 136 (56-180) | .05* |
| Median platelets, ×109/L (range) | 380.5 (45-1392) | 386 (49-1089) | 410 (42-1088) | 379 (75-2011) | .95 |
| Median LDH, U/L (range) | 712 (193-2981) | 745 (162-2497) | 600 (120-1958) | 700 (225-2166) | .83 |
| Blast ≥1, no. (%) | 10 (58.8) | 9 (33.3) | 7 (35) | 12 (50) | .21 |
| Median CD34+ cell, % (range) | 0.23 (0-3.1) | 0.19 (0.01-34) | 0.09 (0.02-3.43) | 0.25 (0.02-1.32) | .98 |
| Median CD34+ cell, ×109/L (range) | 22.8 (1.4-244) | 17.54 (0.26-800) | 7.06 (2.72-476) | 43.0 (3.0-130.0) | .93 |
| Splenomegaly >15 cm from LCM, no. (%) | 1 (5.8) | 7 (16.2) | 8 (25.8) | 9 (25.0) | .003* |
| Constitutional symptoms, % | 4 (23.5) | 11 (25.6) | 6 (19.3) | 17 (47.2) | .04* |
| Leukemia transformation, no. (%) | 0 | 4 (9.3) | 2 (6.4) | 3 (8.3) | .09 |
| Deaths, no. (%) | 6 (35.3) | 7 (16.3) | 1 (3.2) | 1 (2.8) | .007* |
— indicates not applicable; and LCM, left costal margin.
Statistically significant difference.